Publications by authors named "Shaleigh A Smith"
Article Synopsis
- - Accurate understanding of genetic ancestry is essential for addressing cancer disparities, and new methods using clinical sequencing panels allow for better integration of ancestry analysis in diagnostic settings.
- - In a study of over 45,000 cancer patients, researchers found that ancestry influences the frequency of genetic mutations, revealing some known and novel associations, as well as differences in clinically actionable alterations.
- - Despite similar rates of key genetic changes by ancestry group, a lower percentage of patients with African ancestry had actionable alterations compared to those with European ancestry, highlighting inequities in how precision oncology serves different populations.
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a comparative genetic analysis of 2,138 sarcomas representing 45 pathological entities.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic progression is the leading cause of death in cancer patients, yet the specific genomic mechanisms behind it are not well understood.
- Researchers analyzed data from over 25,000 cancer patients in the MSK-MET cohort, discovering connections between genomic changes and how various tumors spread in 50 different cancer types.
- The study revealed that chromosomal instability is linked to metastatic spread in certain cancers (like prostate and lung adenocarcinomas) but not others (like colorectal cancer), providing insights into how these genomic alterations affect cancer progression and spread to specific organs.
During the past decade, next-generation sequencing (NGS) technologies have become widely adopted in cancer research and clinical care. Common applications within the clinical setting include patient stratification into relevant molecular subtypes, identification of biomarkers of response and resistance to targeted and systemic therapies, assessment of heritable cancer risk based on known pathogenic variants, and longitudinal monitoring of treatment response. The need for efficient downstream processing and reliable interpretation of sequencing data has led to the development of novel algorithms and computational pipelines, as well as structured knowledge bases that link genomic alterations to currently available drugs and ongoing clinical trials.
View Article and Find Full Text PDF